All In Biotech

Drug Trial Radar · NCT06687174

Study to Evaluate the Efficacy and Safety of MY008211A in Subjects with Primary Immunoglobulin a Nephropathy (IgAN)

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate the Efficacy and Safety of MY008211A in Subjects with Primary Immunoglobulin a Nephropathy (IgAN)

Last checked: Nov 20, 2026Latest source record: Nov 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

72

Planned (sponsor's estimate)

Start

Dec 31, 2024

Primary completion

Jun 15, 2026

Study completion Jan 31, 2028

Sponsor

Sponsor type
Industry
First posted
Nov 13, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Efficacy and safety of MY008211A in IgAN patients

Conditions

  • IgA Nephropathy (IgAN)

Interventions

  • MY008211A tabletsDrug

    MY008211A BID

  • MY008211A tablets matched placeboDrug

    Matching placebo to MY008211A taken twice a day.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The ratio of urine protein to creatinine concentration ratio (UPCR based on 24h urine collection, 24h-UPCR) relative to baseline at Week 12.Time frame: Week 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University First Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.